MYOMO, INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(Unaudited)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
For the Three Months ended |
|
|
For the Nine Months Ended |
|
|
|
September 30, |
|
|
September 30, |
|
|
|
2025 |
|
|
2024 |
|
|
2025 |
|
|
2024 |
|
Revenue |
|
$ |
10,090,699 |
|
|
$ |
9,207,586 |
|
|
$ |
29,574,746 |
|
|
$ |
20,482,742 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cost of revenue |
|
|
3,648,451 |
|
|
|
2,262,031 |
|
|
|
10,470,696 |
|
|
|
5,912,632 |
|
Gross profit |
|
|
6,442,248 |
|
|
|
6,945,555 |
|
|
|
19,104,050 |
|
|
|
14,570,110 |
|
Operating expenses: |
|
|
|
|
|
|
|
|
|
|
|
|
Research and development |
|
|
1,527,660 |
|
|
|
1,248,870 |
|
|
|
5,319,015 |
|
|
|
3,212,309 |
|
Selling, clinical and marketing |
|
|
5,254,246 |
|
|
|
3,401,182 |
|
|
|
14,883,936 |
|
|
|
8,540,161 |
|
General and administrative |
|
|
3,177,856 |
|
|
|
3,253,056 |
|
|
|
10,529,188 |
|
|
|
8,779,024 |
|
|
|
|
9,959,762 |
|
|
|
7,903,108 |
|
|
|
30,732,139 |
|
|
|
20,531,494 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Loss from operations |
|
|
(3,517,514 |
) |
|
|
(957,553 |
) |
|
|
(11,628,089 |
) |
|
|
(5,961,384 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
Other expense (income), net |
|
|
|
|
|
|
|
|
|
|
|
|
Interest expense (income), net |
|
|
9,743 |
|
|
|
(76,020 |
) |
|
|
(288,797 |
) |
|
|
(318,555 |
) |
|
|
|
9,743 |
|
|
|
(76,020 |
) |
|
|
(288,797 |
) |
|
|
(318,555 |
) |
Loss before income taxes |
|
|
(3,527,257 |
) |
|
|
(881,533 |
) |
|
|
(11,339,292 |
) |
|
|
(5,642,829 |
) |
Income tax expense |
|
|
135,658 |
|
|
|
84,876 |
|
|
|
420,654 |
|
|
|
280,819 |
|
Net loss |
|
$ |
(3,662,915 |
) |
|
$ |
(966,409 |
) |
|
$ |
(11,759,946 |
) |
|
$ |
(5,923,648 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
Weighted average number of common shares outstanding: |
|
|
|
|
|
|
|
|
|
|
|
|
Basic and diluted |
|
|
42,168,120 |
|
|
|
37,950,515 |
|
|
|
41,737,724 |
|
|
|
37,359,366 |
|
Net loss per share attributable to common stockholders |
|
|
|
|
|
|
|
|
|
|
|
|
Basic and diluted |
|
$ |
(0.09 |
) |
|
$ |
(0.03 |
) |
|
$ |
(0.28 |
) |
|
$ |
(0.16 |
) |
